Skip to main content

Table 3 Patients and tumor characteristics in dependence of the intratumoral OCT3 mRNA expression

From: Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

Characteristics OCT3 (SLC22A3)
Low expression
(< Median)
OCT3 (SLC22A3)
High expression
(≥ Median)
P-value
N 23 26  
Median follow-up in days (range) 348 (22-1531) 423 (29-1645) n.s. (0.36)
Male/female (n) 21/2 22/4 n.s. (0.67)
Median age in years (range) 71 (35-84) 64 (47-93) n.s. (0.13)
1-3 nodules/multiple nodules (specimen) 16/7 18/8 n.s. (0.98)
Tumor diameter < 3 cm/> 3 cm 7/16 11/15 n.s. (0.55)
Median tumor diameter in cm (range) 5.0 (1.5-30) 4.4 (0.1-20) n.s. (0.98)
T classification: T1/T2/T3 (specimen) 6/9/8 10/11/5 n.s. (0.42)
Grading: G1/G2/G3/Gx 3/15/5/0 6/15/4/1 n.s. (0.60)
AFP > 100/< 100 * 4/17 7/19 n.s. (0.73)
Angioinvasion yes/no # 3/18 7/17 n.s. (0.30)
Child A/B/C/no cirrhosis 11/0/1/11 7/4/5/10 n.s. (0.06)
Underlying disease (HCV/HBV/alcoholic/others/unknown) 5/2/2/6/8 4/6/2/8/6 n.s. (0.64)
SLC22A1 mRNA expression
ratio HCC/TST (range)
0.08
(0.001-1.36)
0.4
(0.003-2.78)
0.008
Pretreatment with chemoembolization (yes/no) 6/17 14/12 n.s. (0.08)
Liver transplantation/resection 6/17 13/13 n.s. (0.14)
  1. Median: 0.658 * 2 unknown # 4 unknown
\